Search - tctmd.com

Displaying 1 - 18 of 18

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Daily News

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

L.A. McKeown

December 16, 2022

News Daily News

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

Michael O'Riordan

October 20, 2022

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

L.A. McKeown

January 20, 2022

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

Shelley Wood

June 22, 2021

News Conference News TCT 2020

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Michael O'Riordan

October 14, 2020

News Daily News

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Michael O'Riordan

August 28, 2020

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Daily News

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Michael O'Riordan

April 22, 2020

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

L.A. McKeown

April 01, 2020

News Daily News

NOACs Significantly Curb Risk of VTE in Cancer Patients

L.A. McKeown

December 06, 2018

News Daily News

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Yael L. Maxwell

January 01, 2014

News Daily News

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

Yael L. Maxwell

January 01, 2014

News Daily News

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

L.A. McKeown

July 05, 2013

News Daily News

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

L.A. McKeown

July 05, 2013

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

OSCAR Supports Rivaroxaban for Secondary VTE Prevention in Cancer

Apixaban Tops Rivaroxaban in AF Patients With Valve Disease, Claims Data Suggest

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

Interventionalists, Including PERTs, Grapple With VTE Risks of COVID-19

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

How COVID-19 Promotes Thrombosis, Posing Problems for Drug-Drug Interactions

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

NOACs Significantly Curb Risk of VTE in Cancer Patients

Similar Efficacy, Less Bleeding With Dabigatran vs. Warfarin in VTE Patients

Eficacia Similar y Menos Hemorragias con Dabigatran que con Warfarina en Pacientes TEV

El Apixaban No es Inferior a la Terapia Estándar en el Tratamiento de los Tromboembolismos Venosos Agudos

Apixaban Noninferior to Standard Therapy for Acute Venous Thromboembolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content